MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT - News) today announced that a federal jury found that Boston Scientific Corporation has infringed three patents owned by Medtronic, and awarded Medtronic $250 million in damages.
Medtronic sued Boston Scientific in 2006 asserting that Boston’s Taxus Express2, Express2, Liberte, Maverick, Maverick2, and Quantum Maverick products infringed the Fitzmaurice and Anderson catheter patents owned by Medtronic. The trial began on Friday, May 16, 2008.
The Fitzmaurice patents cover angioplasty catheters with narrowed distal ends, which improve the deliverability of angioplasty catheters. The Anderson patent covers semicompliant angioplasty balloons. The Anderson balloons provide sufficient strength to withstand repeated inflations allowing custom vessel sizing.
About Medtronic
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health, and extending life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s Annual Report on Form 10-K for the year ended April 27, 2007. Actual results may differ materially from anticipated results.
Contact: Medtronic, Inc. Public Relations Marybeth Thorsgaard, 763-505-2644 or Investor Relations Jeff Warren, 763-505-2696
Source: Medtronic, Inc.
